Desensitizations for Chemotherapy and Monoclonal Antibodies: Indications and Outcomes

作者：Blatman Karen S Hsu^*; Castells Mariana C

来源：Current Allergy and Asthma Reports, 2014, 14(8): 453.

DOI：10.1007/s11882-014-0453-5

• Anaphylaxis
• Allergy
• Hypersensitivity
• Desensitization
• Monoclonal antibodies
• Chemotherapy
• Carboplatin
• Cisplatin
• Oxaliplatin
• Taxanes
• Paclitaxel
• Rituximab
• Infliximab
• Trastuzumab
• Skin testing
• Basophil activation test
• Acute infusion reaction

Acute infusion reactions to both chemotherapeutic agents and humanized monoclonal antibodies can occur, which may limit therapeutic options for treatment of malignancies and chronic inflammatory diseases. Many of these acute infusion reactions are consistent with a type I hypersensitivity reaction, including anaphylaxis. If a patient experiences a significant acute infusion reaction, often the recommendation is to discontinue the medication and find an alternative agent. However, the "second-line" agent may be more toxic or inferior. If the reaction is likely a type I or type IV hypersensitivity reaction, one option is to undergo desensitization to the offending drug. Drug desensitization is the process of readministering a needed drug in incremental doses over hours or days until a full therapeutic dose is tolerated. This article will review the current literature on indications and outcomes for drug desensitization in the management of allergy to either chemotherapeutic agents or monoclonal antibodies.

• 出版日期2014-8